An observational study in ST Elevated Myocardial Infarction Undergoing Mechanical Reperfusion, sponsored by Università degli Studi del Piemonte Orientale Amedeo Avogadro. Status unknown at 1 site in Italy. Per ClinicalTrials.gov, last updated 2020-06-11.
Sponsored by Università degli Studi del Piemonte Orientale Amedeo Avogadro · Observational
The ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.
This is a retrospective multicenter registry including at least 40 European primary PCI centers with > 120 primary PCI/year (with expected average > 10/month), with the case load of STEMI not expected to be affected by a potential planned reorganization of the STEMI network. The inclusion period will be of 2 months (from March 1st until April 30th). The data will be compared with those retrospectively collected in the same time window of 2019.
Inclusion criteria: STEMI treated by primary angioplasty. Primary study outcome: Number of STEMI patients undergoing primary angioplasty. Secondary study outcomes: Ischemia time and the number of late presenters (> 12 hours from symptoms onset); 3) Door-to-balloon time and the number of patients with a DTB > 30 minutes); 4) In-Hospital mortality.
Data Collection: Data will be collected anonymized through a dedicated CRF. Each center will identify a local Principal Investigator. We will collect information on the study center, demographic, clinical, procedural data. Furthermore, we will collect data on total ischemia time, door-to-balloon time, type of access to the emergency system, COVID positivity, PCI procedure, data on in-hospital mortality.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 6,609 is above the median of 500 across 983 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →Università degli Studi del Piemonte Orientale Amedeo Avogadro is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
STEMI Patients undergoing mechanical reperfusion
Inclusion Criteria: STEMI Patients undergoing mechanical reperfusion
-
Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2019
Device: Percutaneous Coronary Revascularization for STEMI
Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2020
Device: Percutaneous Coronary Revascularization for STEMI
Percutaneous Mechanical Reperfusion for STEMI
Also known as: Primary angioplasty
Number of patients undergoing primary angioplasty
Number of patients undergoing primary angioplasty
Time frame: March April 2019 and 2020
Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset;
Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;
Time frame: March April 2019 and 2020
Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission
Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission
Time frame: March April 2019 and 2020
In-hospital mortality
In-Hospital mortality
Time frame: March April 2019 and 2020
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Università degli Studi del Piemonte Orientale Amedeo Avogadro